Repligen (NASDAQ:RGEN) Raised to “Hold” at StockNews.com

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a research report sent to investors on Monday morning.

Several other research analysts also recently weighed in on the stock. Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price for the company. TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Royal Bank of Canada increased their price target on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. Finally, Canaccord Genuity Group dropped their price objective on Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a report on Wednesday, April 16th. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $176.82.

Repligen Price Performance

RGEN opened at $143.63 on Monday. The company has a 50 day moving average of $139.66 and a two-hundred day moving average of $145.97. Repligen has a 52-week low of $102.97 and a 52-week high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.06 billion, a P/E ratio of -281.63, a P/E/G ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million during the quarter, compared to analysts’ expectations of $167.58 million. On average, analysts expect that Repligen will post 1.72 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the purchase, the director now directly owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 1.20% of the stock is owned by company insiders.

Institutional Trading of Repligen

Several large investors have recently added to or reduced their stakes in the business. Signaturefd LLC lifted its position in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 124 shares during the period. Sava Infond d.o.o. acquired a new position in Repligen in the 4th quarter valued at approximately $29,000. Raiffeisen Bank International AG purchased a new stake in Repligen in the 4th quarter worth approximately $29,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Repligen during the 4th quarter valued at $40,000. Finally, Center for Financial Planning Inc. grew its holdings in shares of Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 193 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.